Determinants of lipid profile in renal transplant recipients

Fabbian, Fabio; Squerzanti, R; Lambertini, D; Gilli, P

doi:10.1016/s0272-6386(97)90110-4

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Risk factors reported to contribute to the development of dyslipidemia in transplant recipients are age, proteinuria, obesity, antihypertensive therapy, prednisone dosage, pretransplantation hyperlipidemia, treatment with CsA, male gender, renal dysfunction, diabetes mellitus, and treatment with sirolimus (8,31–33,35–38), but the cumulative dose of corticosteroid appears to be the most significant risk factor. The combined use of corticosteroids and CsA appears to be an additive risk factor (31,33,39–41). Studies in kidney‐, heart‐, and liver‐transplant recipients have consistently shown a reduced incidence of hyperlipidemia with FK506 (23,29,42–45).…”

Section: Dyslipidemiamentioning

confidence: 99%

Cardiovascular Toxicities of Immunosuppressive Agents

Miller

2002

American Journal of Transplantation

401

257

View full text Add to dashboard Cite

Cardiovascular disease is one of the major causes of morbidity and mortality following solid organ transplantation. Many of the current immunosuppressive drugs are associated with an increase of one or more risk factors for the development of atherosclerosis. This review compares the mechanism by which individual immunosuppressive agents may impact on these risk factors and the differential contribution of cyclosporine, tacrolimus, mycophenolate, azathioprine, and Rapamycin to these individual risk factors. Attention to the potential cardiovascular toxicities of individual immunosuppressive agents may help design strategies for maintenance of immunosuppression tailored to individual patients.

show abstract

Section: Dyslipidemiamentioning

confidence: 99%